Novel Taxol® formulation: Polyvinylpyrrolidone nanoparticle- encapsulated Taxol® for drug delivery in cancer therapy

Oncology Research

Volumn 8, Issue 7-8, 1996, Pages 281-286

  Sharma, Dayanand ^a   Chelvi, Tamiz P ^a   Kaur, Jatinder ^a   Chakravorty, Ketaki ^b   De Tapas, K ^b   Maitra, Amarnath ^b   Ralhan, Ranju ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF DELHI   (India)

Author keywords

cancer therapy; drug delivery; melanoma; nanoparticles; polyvinylpyrrolidone; Taxol

Indexed keywords

CREMOPHOR; NANOPARTICLE; PACLITAXEL; POVIDONE IODINE; ANTINEOPLASTIC AGENT; POVIDONE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER THERAPY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; HYPERSENSITIVITY REACTION; INTRAVENOUS DRUG ADMINISTRATION; LIGHT SCATTERING; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SURVIVAL TIME; ANIMAL; C57BL MOUSE; CANCER TRANSPLANTATION; DRUG SCREENING; EMULSION; EXPERIMENTAL MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG COMPOUNDING; DRUG SCREENING ASSAYS, ANTITUMOR; EMULSIONS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; PACLITAXEL; PARTICLE SIZE; POVIDONE;

EID: 0029658463     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. 1. Long, H. J. Paclitaxel (Taxol): a novel anticancer chemotherapeutic drug. Mayo Clin. Proc. 69:341-345; 1994.
2. 2. Cahan, M. A.; Walter, K. A., Colvin, O. M.; Brem, H. Cytotoxicity of Taxol in vitro against human and rat malignant brain tumors. Cancer Chemother. Pharmacol. 33: 441-444; 1994.
3. 3. Wiernik, P. H., Einzig, A. I. Taxol in malignant melanoma. Monogr. Natl. Cancer Inst. 15:185-187; 1993.
4. 4. Arbuck, S. G.; Christian, M. C.; Fisherman, J. S.; Cazenave, L. A.; Sarosy, G.; Suffness, M.; Adams, J.; Canetta, R.; Cole, K. E.; Friedman, M. A. Clinical development of Taxol. Monogr Natl. Cancer Inst. 15:11-24; 1993.
5. 5. Fao, R.; Norton, L.; Seidman, A. D. Taxol (paclitaxel): a novel anti-microtubule agent with remarkable anti-neoplastic activity. Int. J. Clin. Lab. Res. 24:6-14; 1994.
6. 6. Weiss, R. B.; Donehower, R. C.; Wiernik, P. H.; Ohnuma, T.; Gralla, R. J.; Trump, D. L.; Baker, J. R.; Van Echo, D. A.; VonHoff, D. D.; Leyland Jones, B. Hypersensitivity reactions from Taxol. J. Clin. Oncol. 8:1263-1268; 1990.
7. 7. Enzig, A. I.; Wiernik, P. H.; Sasloff, J. Garl, S.; Runowicz, C.; O'Hanlon, K. A.; Goldberg, G. Phase II study and long term followup of patients treated with Taxol for advanced ovarian adenocarcinoma. J. Clin. Oncol. 10:1748-1753; 1992.
8. 8. Rogers, B. B. Taxol: a promising new drug of the 90's. Oncol. Nurs. Forum 20:1483-1489; 1993.
9. 9. Straubinger, R. M.; Sharma, A.; Murray, M.; Mayhew, E. Novel Taxol formulations. Taxol containing liposomes Monogr. Natl. Cancer Inst. 15:69-78; 1993.
10. 10. Sharma, A.; Maythew, E.; Straubinger, R. M. Antitumor effect of Taxol-containing liposomes in a Taxol-resistant murine tumor model. Cancer Res. 53: 5877-5881; 1993.
11. 11. Treat, A.; Greenspan, A.; Forst, D.; Sanchez, J. A.; Ferrans, V. J.; Potkul, L. A.; Woolley, P. V.; Rahman, A. Antitumor activity of liposomal encapsulated doxorubicin in advanced breast cancer: phase II study. J. Natl. Cancer Inst. 82:1706-1709; 1990.
12. 12. Hwang, K. L.; Luk, K. K.; Beaumier, P. L. Liposomes: a kinetic study. Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol. Proc. Natl. Acad. Sci. USA 77:4030-4034; 1980.
13. 13. Ostro, M. J., ed. Liposomes from biophysics to therapeutics. New York. Dekker; 1987:pp. 1-369.
14. 14. Allen, T. M.; Hansen, C.; Rutledge, J. Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. Biochim. Biophys. Acta 981:27-35; 1989.
15. 15. Papahadjopoulos, D.; Allen, T. M.; Gabizon, A. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc. Natl. Acad. Sci. USA 88:11460-11464; 1991.
16. 16. Gabizon, A. A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res. 52: 2431-2439; 1992.
17. 17. Vaage, J.; Mayhew, E.; Lasic, D.; Martin, F. Therapy of primary and metastatic mouse mammary carcinomas with doxorubicin encapsulated in long-circulating liposomes. Int. J. Cancer 51:942-948; 1992.
18. 18. Yatvin, M. B. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202: 1290-1292; 1978.
19. 19. Chelvi, T. P.; Ralhan, R. Designing of heat sensitive liposomes from natural lipids for multimodality cancer therapy. Int. J. Hyperthermia 11:685-695; 1995.
20. 20. Chelvi, T. P.; Jain, S. K.; Ralhan, R. Hyperthermia-mediated targeted delivery of thermosensitive liposome-encapsulated melphalan in murine tumors. Oncol. Res. 7:393-398; 1995.
21. 21. Davis, S. S.; Illum, L.; Moghimi, S. M.; Daviers M. C., Porter, C. J. H.; Muir, I. S.; Brindley, A.; Christy, N. M.; Norman, M. E.; Williams, P.; Dunn, S. E. Microspheres for targeting drugs to specific body sites. J. Controlled Release 24:157-163; 1993.
22. 22. Illum, L.; Davis, S. S. The organ uptake of intravenously administered colloidal particles can be altered using a nonionic surfactant (poloxamer 338). FEBS Lett. 167: 79-82; 1984.
23. 23. Munshi, N.; Chakravorty K.; De, T. K.; Maitra, A. N. Activity and stability studies of ultrafine nanoencapsulated catalase and penicillinase. Colloid Polym. Sci. 273: 464-472; 1995.
24. 24. Bite, S. Cancer incidence and mortality trends. J. Natl. Cancer Inst. 84:1862-1866; 1992.
25. 25. Liebmann, J. E.; Cooks, J. A.; Lipschultz, C.; Teague, D.; Fisher, J.; Mitchell, J. B. Cytotoxic studies of paclitaxel (Taxol) in human tumour cell lines. Br. J. Cancer 68:1104-1109; 1993.
26. 26. Ficek, B. J.; Peppas, N. A. Novel preparation of poly (vinylalcohol) microparticles without crosslinking agent for controlled drug delivery of proteins. J. Controlled Release 27:259-264; 1993.
27. 27. Couvreur, P.; Fattal, E.; Alphandary, H.; Puisieux, F.; Andremont, A. Intracellular targeting of antibiotics by means of biodegradable nanoparticles. J. Controlled Release 19:259-268; 1992.
28. 28. Shalaby, W. S. W.; Blevins, W. E.; Park, K. In vitro and in vivo studies of enzyme-digestible hydrogels for oral drug delivery. J. Controlled Release 19:131-144; 1992.
29. 29. Hashida, M.; Takakura, Y. Pharmacokinetics in design of polymeric drug delivery systems. J. Controlled Release 31:163-171; 1994.
30. 30. Illum, L.; Jacobsen, L. O.; Muler, R. H.; Mak, E.; Davis, S. S. Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. Biomaterials 8:113-117; 1987.
31. 31. Shieh, L.; Tamada, J.; Tabata, Y.; Domb, A.; Langer, R. Drug release from a new family of biodegradable polyanhydrides. J. Controlled Release 29:73-82; 1994.